Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy

January 5, 2021

Lobo, S., Baczyk, P., Wyss, B., et al.

Journal of Pharmaceutical and Biomedical Analysis 2021, vol: 192 doi: 10.1016/j.jpba.2020.113650

In this publication, Novartis investigates strategies for optimizing non-IgG based therapeutic proteins. Non-IgG therapeutics often have a greater number of attributes to evaluate, which increases their complexity. Further, unlike with monoclonal antibodies (mAbs), there are often not huge libraries of candidates to triage and screen for optimal stability. The group looked at how to best assess stability attributes of non-IgG proteins, using low sample volumes and high throughput.


4 key takeaways from this publication: 

1. Thermal stability is a critical quality attribute to measure for any therapeutic protein, and because non-IgG therapeutic proteins have less flexibility for sequence optimization, buffer selection is an additional critical step for any new protein therapy

2. nano-Differential Scanning Fluorimetry (nanoDSF) enables rapid thermal stability assessment with only a few microlitres of sample

3. Self-interaction measurements using Dynamic Light Scattering (DLS), in several different buffers, help inform on the propensity of a protein therapeutic to aggregate or become viscous

4. Size exclusion chromatography (SEC) is useful for the assessment of oligomerization species, especially when a prep has multiple oligomeric states present

View Publication

Topics: Prometheus, nanoDSF, Biologics, Publications

Previous Article
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry

Up next
How Janssen optimizes the stability of a therapeutic mAb
How Janssen optimizes the stability of a therapeutic mAb

Discover how Janssen improved the stability of a promising prostate cancer targeting mAb. You’ll learn why ...

Want to see more
biologics content?

Explore resources